| Schedule of Segment Information |
The following table sets forth the Company’s segment information (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated |
|
|
Consolidated |
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
Direct external expenses by program |
|
|
|
|
|
|
|
|
|
|
|
|
Zidesamtinib |
|
$ |
(17,280 |
) |
|
$ |
(14,886 |
) |
|
$ |
(32,831 |
) |
|
$ |
(25,252 |
) |
Neladalkib |
|
|
(28,298 |
) |
|
|
(14,196 |
) |
|
|
(56,305 |
) |
|
|
(23,927 |
) |
NVL-330 |
|
|
(5,928 |
) |
|
|
(1,738 |
) |
|
|
(9,889 |
) |
|
|
(3,710 |
) |
Discovery programs |
|
|
(3,416 |
) |
|
|
(2,450 |
) |
|
|
(5,549 |
) |
|
|
(4,550 |
) |
Personnel-related expenses (including stock-based compensation) |
|
|
(38,765 |
) |
|
|
(25,066 |
) |
|
|
(74,073 |
) |
|
|
(48,394 |
) |
General and administrative professional and consultant fees |
|
|
(3,077 |
) |
|
|
(2,652 |
) |
|
|
(5,943 |
) |
|
|
(4,677 |
) |
Change in fair value of related party revenue share liability |
|
|
(6,040 |
) |
|
|
— |
|
|
|
(7,470 |
) |
|
|
— |
|
Interest income |
|
|
11,118 |
|
|
|
8,150 |
|
|
|
22,953 |
|
|
|
16,645 |
|
Other segment items(1) |
|
|
(7,822 |
) |
|
|
(4,158 |
) |
|
|
(14,826 |
) |
|
|
(7,230 |
) |
Income tax provision |
|
|
(145 |
) |
|
|
(170 |
) |
|
|
(302 |
) |
|
|
(553 |
) |
Consolidated net loss |
|
$ |
(99,653 |
) |
|
$ |
(57,166 |
) |
|
$ |
(184,235 |
) |
|
$ |
(101,648 |
) |
(1) Other segment items included in consolidated net loss include expenses for research and development consulting services, commercialization preparation activities, information technology, insurance, and other miscellaneous activities.
|